Question special

One might have expected that in a trial (with no run-in apart from demonstrating the ability to take a placebo injection) of a treatment given by injection, at home, every 2 weeks that adherence may have been an issue and that many might have stopped treatment. However, less than 6% stopped treatment per year and this is backed up by the difference in LDL-c between treatment arms which stayed the same over time. Was this expected and do the authors have any comments or advice on how to achieve similar adherence, whether in future trials or in clinical practice?